The case of a patient with cysts in the iliac bone is presented as an atypical cause of chronic low back pain that the rheumatologist may face, and a review of the literature on the types of bone cysts and their differential diagnoses will be made. Mention will also be made of your treatment options.
BackgroundBehcet’s disease (BD) is characterized by oral, genital, and gastrointestinal manifestations. The pathergy test is used as a diagnostic tool, but this is not specific to BD, since it can be found in other diseases and can equally be negative even having the disease.Another characteristic of BD is the vascular compromise, predominantly venous. In a study, the measurement of the thickness of the common femoral vein (CVF) proved to be a diagnostic test with sensitivity and specificity greater than 80% for the cut-off value of 0.5 mm.ObjectivesTo evaluate the diagnostic performance of the thickness of the posterior wall of the common femoral vein, measured by Doppler ultrasound for the diagnosis of Behcet’s disease.MethodsA multicenter pilot study was carried out to evaluate a diagnostic test. Data were collected by reviewing medical records collected from patients who met the 2014 International Criteria for Behcet’s Disease (ICBD), and healthy controls. Venous Doppler ultrasound of the lower limbs was performed in both groups using an ultrasound evaluation protocol, considering posterior wall thickness of the CFV ≥ 0.5 mm as positive.Results19 patients with EB and 19 healthy controls were included. The mean age of patients with DB was 47 (SD 12.6), and the median age of healthy patients was 41 years (IQR 36.5-48.5). 57.89% were mestizo in the BD group and 68.42% in the control group.The median delay in diagnosis was 19 months (IQR 11-36). The presence of HLA B51 was 63.15% and the positive pathergy test was found in 31.57%. At the time of the study, 42.10% had disease activity and a mean of 8.8 years of disease. (Table 1)The ultrasound was positive in 89.4% of patients with BD and 10.5% in the healthy group, observing a sensitivity of 94.1% and a specificity of 94.7%, with an area under the curve 0.89 (p < 0.0001), PPV 94.1% and NPV 94.7%. (Fig. 1)We observe a post-test probability of 0.059. The test presents LR + 17.8 (95%CI 2.5-127) and LR - 0.06 (95%CI 0.008-0.4)ConclusionThe diagnosis of Behcet’s disease is difficult because it is based mainly on clinical manifestations, so this ultrasound test has a good capacity to be used as part of the diagnosis in patients with clinical suspicion, since it has a good sensitivity and specificity profile, low cost and simplicity.References[1]Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65: 1–11.[2]Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Bechet’s disease: an update. Curr Opin Rheumatol 2011; 23:24–31.[3]Alibaz-Oner F, Ergelen R, Yildiz Y, Aldag M, Yazici A, Cefle A, Koç E, Artim Esen B, Mumcu G, Ergun T, Direskeneli H. Femoral vein wall thickness measurement: A new diagnostic tool for Behçet’s disease. Rheumatology (Oxford). 2021 Jan 5;60(1):288-296. doi: 10.1093/rheumatology/keaa264. PMID: 32756998.[4]Tezcan D, Özer H, Gülcemal S, Hakbilen S, Durmaz MS, Batur A, Yilmaz S. Diagnostic Performance of Lower Extremity Venous Wall Thickness and Laboratory Findings in the Diagnosis of the Behçet Disease. J Clin Rheumatol. 2022 Mar 1;28(2):e521-e527. doi: 10.1097/RHU.0000000000001788. PMID: 34538847.Table 1Demographic, clinical and treatment characteristics.Fig. 1ROC CurveAcknowledgements:NIL.Disclosure of InterestsNone Declared.
BackgroundInterstitial lung disease (ILD) and pulmonary arterial hypertension (PHT) account for 60% of deaths related to scleroderma (SSc) [1]. The Red Cell Distribution Width (RDW) is a biomarker that has been used as a marker of poor prognosis in various pathologies[2-9]. In SSc, the RDW has been found to be elevated in PHT and has been proposed as a predictor of cardiorespiratory compromise[10-11].ObjectivesTo evaluate the association between the increase in RDW and the presence of ILD in patients with SSc.MethodsObservational, retrospective, multicenter, cross-sectional study of patients with SSc (ACR/ EULAR 2013) between 1/1/2011 to 8/31/2021. Other concomitant autoimmune diseases, malignancy, active infections, anemia, recent transfusions, cardiovascular, renal, or hepatic disease were excluded. The diagnosis of ILD was made by high-resolution computed tomography (HRCT) and the extension evaluated by Goh criteria¹². A review of medical records was performed, collecting relevant clinical and demographic characteristics.ResultsSeventy-five patients were included, with a mean age of 59.4 years (SD 14.1, 95% CI 56-63), 67 (89%) were women. A median of 8 years of disease evolution was observed (IQR 8). ILD was observed in 50 (66,6%) patients while 25 (33.3%) did not. According to Leroy’s classification, limited SSc (lcSSc) was observed in 50 patients (66,6%) and diffuse SSc (dSSc) in 24 (33,3%); the last classification was significantly associated with the presence of ILD, as was as MRSS (Modified Rodnan Skin Thickness Score)> 14, digital ulcers, and positive ATA (DNA topoisomerase I), unlike ACA (anticentromere antibodies) (Table 1).The most frequent HRCT pattern was NSIP (Nonspecific interstitial pneumonia) in lcSSc (66.6%). An association was found between dSSc and fibrotic patterns (fNSIP and UIP). OR 6, 95% CI 1.6-21 (p 0.009).The extension of the disease was measured in 44 patients (6 missing data), being limited in 25 (57%) and extensive in 19 (43%). The extensive form was correlated with a higher RDW mean (p < 0.0001).The MRSS was measured in 70 patients, being less than 14 in 63 (90%). 100% of the patients with mRSS > 14 had a high RDW (p 0.01).Increased RDW was evidenced in the group with ILD, with a statistically significant difference (OR 6.06 95%CI 2-17 p 0.001).The median RDW in the groups with isolated ILD and ILD plus PHT was significantly higher than in patients without lung disease (p < 0.001). We found no significant difference between the ILD and ILD plus PHT groups (p 0.350) (Figure 1).Figure 1.ConclusionWe have been able to show that there is a significant relationship between the increase in RDW and the presence of ILD in patients with SSc; this association was more significant for the extensive forms of the disease as well as fibrotic patterns.These findings are relevant as the RDW is an easily accessible parameter that could be used in the follow-up of patients with SSc, and an elevation not explained by other causes of the RDW could be an alarming marker to search more exhaustively for the presence of cardiorespiratory compromise.The limitations of the study are those of any retrospective study, the presence of missing data in addition to the limited number of patients. It is necessary to continue studies with a larger number of patients to grant robustness to the results.References[1]Muangchan, et al. The Journal of Rheumatology 2013; 40; 9.[2]Cottin and Brown. Respiratory Research (2019) 20:13[3]L. A. Allen et al. Journal of Cardiac Failure, vol. 16, no. 3, pp. 230–238, 2010.[4]S. Dabbah et al. American Journal of Cardiology, vol. 105, no. 3, pp. 312–317, 2010.[5]Abul et al. Chronic Respiratory Disease 2014, Vol. 11(2) 73–81[6]Smukowska-Gorynia A, et al. Heart, Lung and Circulation (2017).[7]Hampole et al. Am J Cardiol 2009;104:868–872[8]Thayer, T. E. et al. Annals of the American Thoracic Society. doi:10.1513/annalsats.201809-594oc.[9]Jie Yang et al. Canadian Respiratory Journal Volume 2019, Article ID 3853454.[10]Farkas N et al (2014) Rheumatology (Oxford) 53:1439–1445.[11]Forhecz Z et al. Am Heart J 2009;158:659-66.Acknowledgements:NIL.Disclosure of InterestsNone Declared.
BackgroundThe clinical manifestations of patients with rheumatic diseases are highly heterogeneous. The appearance of adverse events (AEs) related to the treatments received for these diseases considerably increases the morbidity and mortality of these patients. This is why obtaining real-world data on these AEs and analyzing their causes is paramount. The BIOBADASAR registry has data from 5,676 patients over ten years of follow-up. Classifying patients in treatment with biological drugs into subgroups with different phenotypes through unsupervised grouping could provide valuable information on the characteristics associated with specific AE.ObjectivesThrough cluster analysis, this study aimed to identify different clinical phenotypes related to Adverse events in patients treated with biological drugs.MethodsRetrospective, multicenter study of patients with rheumatic diseases treated with original biological drugs, biosimilars, or original and generic targeted therapies in Argentina; follow-up from August 2010 to July 2021. Demographic and clinical data, time of initiation and completion of treatments, data on disease activity, and the AEs presented were collected.Patients were unbiasedly matched based on their clinical and phenotypic profiles using a k-means pooling method. The initiation of biological disease-modifying antirheumatic drugs (b-DMARD) was evaluated in the segregated groups to investigate each group’s clinical course and differential characteristics.ResultsA total of 5676 patients were analyzed. Three different clusters were obtained:Cluster 1: 1041 patients. Was observed an evolution time of the disease of 30.5 years (Q1 25.8; Q3 35.6) longer than other clusters and a longer delay in starting treatment at 18.3 years (Q114.4; Q3 24) p < 0.0001.Cluster 2: 2136 patients. We observed a higher frequency of patients with Systemic Lupus Erythematosus: 156 (7.3%) p<0.0001 and a lower frequency of AEs 190 (8.9%) p <0.0001Cluster 3: 2499 patients. We observed a higher mean age than in the other two clusters, 57.3 (SD 8.3) p < 0.001.The use of systemic corticosteroids was evenly distributed among the 3 clusters.ConclusionThe unsupervised grouping of patients from the BIOBADASAR registry demonstrated the existence of clusters based on clinical and demographic characteristics. Identifying high-risk patients through a combination of these parameters may be helpful for the early identification of risk factors and their association with adverse events.Based on our hierarchical cluster analysis, we identified different patient phenotypes.Our results show that within the heterogeneity of patient characteristics, common elements provide a basis for future analyses of these variables and their relationship with certain AEs.Graphics 1.K-means cluster analysis graph. Distribution of patients according to the cluster they belong to.Dim1: Principal component 1; Dim2: Principal component 2.REFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsJorge Alejandro Brigante Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Karen Roberts Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Carolina Isnardi Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gimena Gómez Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Maria Haye Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Mercedes García Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Carla Gobbi Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gustavo Casado Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Laura Lucia Holguín Arias Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Joan Manuel Dapeña Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Silvia Papasidero Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Guillermo Berbotto Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Malena Viola Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Veronica Saurit Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Ingrid Petkovic Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Ana Bertoli Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Monica Patricia Diaz Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Erika Catay Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Ida Elena Exeni Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Bernardo Pons-Estel Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gladys Bovea Castelblanco Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Mercedes Elena De La Sota Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Maria Silvia Larroude Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Dora Aida Pereira Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Amelia Beatriz Granel Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gustavo Medina Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Cecilia Pisoni Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., MONICA SACNUN Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Edson Velozo Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Nora Aste Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Cecilia Castro Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Eduardo Kerzberg Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Veronica Savio Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., JULIETA GAMBA Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Anastasia Secco Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gustavo Citera Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Enrique Soriano Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Cesar Graf Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Guillermo Pons-Estel Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Maria de la Vega Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database.
BackgroundMajor Cardiovascular Adverse Events (MCAE) are a concern in autoimmune diseases. Rheumatoid Arthritis (RA) and psoriasis arthritis (PsA) are diseases where inflammation plays a vital role in developing the disease and producing short- and long-term damage.The TNF alpha plays a significant role in inflammation. The JAK/STAT signaling pathway is an essential regulatory signaling cascade of intracellular processes used in treating these conditions. It is crucial to evaluate the effect of these treatments on long-term comorbidities associated with these diseases.ObjectivesThis study aims to provide real-world evidence on the influence of Anti-JAK, Anti-TNFa, and cs-DMARDs therapy on cardiovascular events in RA and PsA.MethodsData from the BIOBADASAR 3.0 registry of patients diagnosed with RA and PsA (ACR-EULAR 2010/ CASPAR 2006) from June 2010 to May 2022. This data was recollected from patients treated with cs-DMARDs (control group), Anti-TNF alpha, and JAK inhibitors. The history of specific comorbidities and the appearance of AE were recorded. Kaplan Meier curves evaluated event-free survival time, and the comparison between the different treatments was performed by Log Rank analysis. Additionally, to account for alternative explanations, a propensity score (PS) was estimated, which assigned a value to each observation according to the probability of incorporating all the information available to estimate this probability and making the groups associating similar patients more comparable.ResultsOf 6,209 patients, 4,817 (77.6%) with RA and 510 (8.2%) with PsA were studied.The overall frequency of MCAE was 48 (2.2%) in the Anti-TNFa group, 5 (2.37%) in the Anti-JAK group, and 38 (1.84%) in the control group (p=0.6).MCAE-free survival was a median in years of 3.02 for the Anti-TNFa group (HR 1.3 95%CI 0.8-384), 5.1 for the control group (HR 1.5 95%CI 0.32-651), and 1.8 for the group with JAK inhibitors (HR 3.02 95% CI 0.2-0.8),The results of the regression model adjusted by PS to present MCAE were for the Anti-TNFa group HR 1.28 IC95% 0.77-2.13 p 0.34, for the non-exposed group HR 1.48 IC95% 0.82-2.67 and the JAK inhibitor group 3.12 IC95% 1.48-6.6 p < 0.001.ConclusionIn conclusion, we found no statistically significant difference between the RA and APS groups appearance of adverse events of interest.In this study, we observed a higher MCAE-free survival time in the not exposed group than in the Anti-TNFa group and considerably low in the Anti-JAK group with a statistically significant difference. These differences persist in the multivariate model adjusted by propensity score.Figure 1.MCAE free-survival time according to treatment.REFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsJorge Alejandro Brigante Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Karen Roberts Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Carolina Ayelen Isnardi Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gimena Gómez Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Laura Lucia Holguín Arias Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Bernardo Pons-Estel Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., JULIETA GAMBA Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Maria Haye Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Joan Manuel Dapeña Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Anastasia Secco Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Veronica Savio Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Carola Soliz Cordero Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Carla Gobbi Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Edson Velozo Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Erika Catay Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Nora Aste Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gustavo Medina Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Ida Elena Exeni Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Graciela Gomez Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Dora Aida Pereira Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Amelia Beatriz Granel Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Ingrid Petkovic Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Cecilia Pisoni Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Andrea Maria Smichowski Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., MONICA SACNUN Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Guillermo Berbotto Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Mercedes García Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Malena Viola Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gladys Bovea Castelblanco Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Veronica Saurit Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Eduardo Kerzberg Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Maria Silvia Larroude Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Mercedes Elena De La Sota Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Ana Bertoli Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Monica Patricia Diaz Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Cecilia Castro Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gustavo Citera Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Gustavo Casado Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Rosana Quintana Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Enrique Soriano Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Cesar Graf Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Guillermo Pons-Estel Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database., Maria de la Vega Grant/research support from: BIOBADASAR has received an unrestricted Grant from Pfizer. Pfizer has not participated in or influenced the project’s development, data collection, analysis, interpretation, or report writing. They do not have access to the information collected in the database.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.